Figure 1

**Pre-treatment**

**Pre-randomization phase**

**Randomization**

**Post-randomization phase**

**Final study visit**

---

Enrolled in study and initiated on LPV/r-based ART

\( n = 323 \)

(168 B, 155 G)

---

Eligible for randomization

(VL < 400 copies/mL and maintained for ≥3 months)

\( n = 195 \)

(104 B, 91 G)

---

Remain on LPV/r

\( n = 99 \)

(50 B, 49 G)

- 3 died
- 10 LTFU
- 1 transferred

Switch to NVP

\( n = 96 \)

(54 B, 42 G)

- 3 died
- 18 LTFU
- 4 transferred

---

Remain on LPV/r

\( n = 85 \)

(41 B, 44 G)

Switch to NVP

\( n = 71 \)

(40 B, 31 G)

---

38 died

40 LTFU/transferred

50 did not achieve sustained viral suppression

---

Enrolled in study and initiated on LPV/r-based ART

\( n = 323 \)

(168 B, 155 G)